{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:36Z","timestamp":1791849396921,"version":"4.3.4"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"DOI":"10.1007\/s13300-026-01926-9","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:33:20Z","timestamp":1791822800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Bidirectional Relationship Between Diabetes and Cancer: Mechanistic Insights, Epigenetic Intermediaries, and Therapeutic Approaches"],"prefix":"10.1007","author":[{"given":"Prahallad","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-2434","authenticated-orcid":false,"given":"Thyparambil Aravindakshan","family":"PramodKumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpal","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradyumna K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pujarini","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-1374","authenticated-orcid":false,"given":"Ranjit Mohan","family":"Anjana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Kumar","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5038-6210","authenticated-orcid":false,"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"6","key":"1926_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.4093\/dmj.2021.0077","volume":"45","author":"DS Kim","year":"2021","unstructured":"Kim DS, Scherer PE. Obesity, diabetes, and increased cancer progression. Diabetes Metab J. 2021;45(6):799\u2013812. https:\/\/doi.org\/10.4093\/dmj.2021.0077.","journal-title":"Diabetes Metab J"},{"key":"1926_CR2","volume-title":"IDF diabetes atlas","author":"International Diabetes Federation","year":"2025","unstructured":"International Diabetes Federation. IDF diabetes atlas. 11th ed. Brussels, Belgium: International Diabetes Federation; 2025.","edition":"11th ed."},{"issue":"7","key":"1926_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s2213-8587(23)00119-5","volume":"11","author":"RM Anjana","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474\u201389. https:\/\/doi.org\/10.1016\/s2213-8587(23)00119-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1926_CR4","first-page":"1","volume":"22","author":"V Mohan","year":"2009","unstructured":"Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India. Health Adm. 2009;22(1):1\u201318.","journal-title":"Health Adm"},{"key":"1926_CR5","first-page":"152","volume":"56","author":"V Mohan","year":"2008","unstructured":"Mohan V, Deepa M, Anjana RM, Lanthorn H, Deepa R. Incidence of diabetes and pre-diabetes in a selected urban south Indian population (CUPS-19). J Assoc Physicians India. 2008;56:152\u20137.","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"1926_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2337\/diacare.8.4.371","volume":"8","author":"V Mohan","year":"1985","unstructured":"Mohan V, Ramachandran A, Snehalatha C, Mohan R, Bharani G, Viswanathan M. High prevalence of maturity-onset diabetes of the young (MODY) among Indians. Diabetes Care. 1985;8(4):371\u20134. https:\/\/doi.org\/10.2337\/diacare.8.4.371.","journal-title":"Diabetes Care"},{"issue":"2","key":"1926_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2337\/dci24-0046","volume":"48","author":"V Mohan","year":"2025","unstructured":"Mohan V. Lessons learned from epidemiology of type\u00a02 diabetes in South Asians: Kelly West Award Lecture 2024. Diabetes Care. 2025;48(2):153\u201363. https:\/\/doi.org\/10.2337\/dci24-0046.","journal-title":"Diabetes Care"},{"issue":"29","key":"1926_CR8","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/eurheartj\/ehaf354","volume":"46","author":"TA PramodKumar","year":"2025","unstructured":"PramodKumar TA, Mohan V. Epidemic of cardio-metabolic disorders in south Asia: need for urgent solutions. Eur Heart J. 2025;46(29):2838\u201340. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf354.","journal-title":"Eur Heart J"},{"key":"1926_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112387","volume":"227","author":"V Mohan","year":"2025","unstructured":"Mohan V, Pramodkumar TA, Deepa M, et al. Lean diabetes is one end of the spectrum of type\u00a02 diabetes and not a separate entity. Diabetes Res Clin Pract. 2025;227:112387. https:\/\/doi.org\/10.1016\/j.diabres.2025.112387.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1926_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1926_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276913","volume":"17","author":"J Gurney","year":"2022","unstructured":"Gurney J, Stanley J, Teng A, et al. Cancer and diabetes co-occurrence: a national study with 44\u00a0million person-years of follow-up. PLoS ONE. 2022;17(11):e0276913. https:\/\/doi.org\/10.1371\/journal.pone.0276913.","journal-title":"PLoS ONE"},{"issue":"6","key":"1926_CR12","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","volume":"6","author":"J Pearson-Stuttard","year":"2018","unstructured":"Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6\u201315. https:\/\/doi.org\/10.1016\/S2213-8587(18)30150-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1926_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.4103\/0366-6999.157693","volume":"128","author":"SC Lee","year":"2015","unstructured":"Lee SC, Chan JC. Evidence for DNA damage as a biological link between diabetes and cancer. Chin Med J (Engl). 2015;128(11):1543\u20138. https:\/\/doi.org\/10.4103\/0366-6999.157693.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"1926_CR14","doi-asserted-by":"publisher","DOI":"10.5041\/rmmj.10043","volume":"2","author":"D Leroith","year":"2011","unstructured":"Leroith D, Scheinman EJ, Bitton-Worms K. The role of insulin and insulin-like growth factors in the increased risk of cancer in diabetes. Rambam Maimonides Med J. 2011;2(2):e0043. https:\/\/doi.org\/10.5041\/rmmj.10043.","journal-title":"Rambam Maimonides Med J"},{"issue":"6","key":"1926_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","volume":"45","author":"L Ouyang","year":"2012","unstructured":"Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487\u201398. https:\/\/doi.org\/10.1111\/j.1365-2184.2012.00845.x.","journal-title":"Cell Prolif"},{"key":"1926_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115015","volume":"164","author":"M Nigam","year":"2023","unstructured":"Nigam M, Mishra AP, Deb VK, et al. Evaluation of the association of chronic inflammation and cancer: insights and implications. Biomed Pharmacother. 2023;164:115015. https:\/\/doi.org\/10.1016\/j.biopha.2023.115015.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1926_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.clinbiochem.2010.12.015","volume":"44","author":"K Indulekha","year":"2011","unstructured":"Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem. 2011;44(4):281\u20137. https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.12.015.","journal-title":"Clin Biochem"},{"issue":"2","key":"1926_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.496","volume":"5","author":"Y Long","year":"2024","unstructured":"Long Y, Mao C, Liu S, Tao Y, Xiao D. Epigenetic modifications in obesity-associated diseases. MedComm (2020). 2024;5(2):e496. https:\/\/doi.org\/10.1002\/mco2.496.","journal-title":"MedComm (2020)"},{"issue":"3","key":"1926_CR19","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/jcp.29180","volume":"235","author":"N Kumari","year":"2020","unstructured":"Kumari N, Karmakar A, Ganesan SK. Targeting epigenetic modifications as a potential therapeutic option for diabetic retinopathy. J Cell Physiol. 2020;235(3):1933\u201347. https:\/\/doi.org\/10.1002\/jcp.29180.","journal-title":"J Cell Physiol"},{"key":"1926_CR20","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_182_24","author":"D Bodhini","year":"2024","unstructured":"Bodhini D, Mohan V, Radha V. Association of vitamin\u00a0D receptor gene variants with diabetic nephropathy: scope for further exploration using epigenetics. J Diabetol. 2024. https:\/\/doi.org\/10.4103\/jod.jod_182_24.","journal-title":"J Diabetol"},{"issue":"7","key":"1926_CR21","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674\u201385. https:\/\/doi.org\/10.2337\/dc10-0666.","journal-title":"Diabetes Care"},{"issue":"1","key":"1926_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11344-w","volume":"23","author":"F Amri","year":"2023","unstructured":"Amri F, Belkhayat C, Yeznasni A, et al. Association between pancreatic cancer and diabetes: insights from a retrospective cohort study. BMC Cancer. 2023;23(1):856. https:\/\/doi.org\/10.1186\/s12885-023-11344-w.","journal-title":"BMC Cancer"},{"issue":"3","key":"1926_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107816","volume":"35","author":"RBN Conway","year":"2021","unstructured":"Conway RBN, Sudenga S, McClain D, Blot WJ. Diabetes and liver cancer risk: a stronger effect in Whites than Blacks? J Diabetes Complicat. 2021;35(3):107816. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107816.","journal-title":"J Diabetes Complicat"},{"key":"1926_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104345","volume":"86","author":"H Zeng","year":"2022","unstructured":"Zeng H, Yuan C, Morze J, et al. New onset of type\u00a02 diabetes after colorectal cancer diagnosis: results from three prospective US cohort studies, systematic review, and meta-analysis. EBioMedicine. 2022;86:104345. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104345.","journal-title":"EBioMedicine"},{"key":"1926_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163453","author":"L Zabuliene","year":"2021","unstructured":"Zabuliene L, Kaceniene A, Steponaviciene L, et al. Risk of endometrial cancer in women with diabetes: a population-based retrospective cohort study. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10163453.","journal-title":"J Clin Med"},{"issue":"7","key":"1926_CR26","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10552-012-9989-7","volume":"23","author":"RJ Cleveland","year":"2012","unstructured":"Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control. 2012;23(7):1193\u2013203. https:\/\/doi.org\/10.1007\/s10552-012-9989-7.","journal-title":"Cancer Causes Control"},{"key":"1926_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1125745","volume":"13","author":"Z Chen","year":"2023","unstructured":"Chen Z, Hong Q. Correlation of serum IGF-1, AGEs and their receptors with the risk of colorectal cancer in patients with type\u00a02 diabetes mellitus. Front Oncol. 2023;13:1125745. https:\/\/doi.org\/10.3389\/fonc.2023.1125745.","journal-title":"Front Oncol"},{"issue":"5","key":"1926_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.urolonc.2012.07.008","volume":"30","author":"BL Pierce","year":"2012","unstructured":"Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol. 2012;30(5):735\u201343. https:\/\/doi.org\/10.1016\/j.urolonc.2012.07.008.","journal-title":"Urol Oncol"},{"key":"1926_CR29","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.12659\/msm.902440","volume":"23","author":"H Han","year":"2017","unstructured":"Han H, Deng H, Han T, Zhao H, Hou F, Qi X. Association between hepatocellular carcinoma and type\u00a02 diabetes mellitus in Chinese hepatitis\u00a0B virus cirrhosis patients: a case-control study. Med Sci Monit. 2017;23:3324\u201334. https:\/\/doi.org\/10.12659\/msm.902440.","journal-title":"Med Sci Monit"},{"issue":"5","key":"1926_CR30","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00125-016-3884-9","volume":"59","author":"B Carstensen","year":"2016","unstructured":"Carstensen B, Read SH, Friis S, et al. Cancer incidence in persons with type\u00a01 diabetes: a five-country study of 9,000 cancers in type\u00a01 diabetic individuals. Diabetologia. 2016;59(5):980\u20138. https:\/\/doi.org\/10.1007\/s00125-016-3884-9.","journal-title":"Diabetologia"},{"issue":"2","key":"1926_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2337\/dc14-1996","volume":"38","author":"JL Harding","year":"2015","unstructured":"Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type\u00a01 and type\u00a02 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264\u201370. https:\/\/doi.org\/10.2337\/dc14-1996.","journal-title":"Diabetes Care"},{"issue":"3","key":"1926_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108129","volume":"36","author":"RP Abhinav","year":"2022","unstructured":"Abhinav RP, Williams J, Bennett C, et al. Frequency and association of self-reported oral cancer among individuals with type\u00a02 diabetes at a tertiary care diabetes centre in South India - a retrospective study. J Diabetes Complicat. 2022;36(3):108129. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108129.","journal-title":"J Diabetes Complicat"},{"issue":"11","key":"1926_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107670","volume":"34","author":"RP Abhinav","year":"2020","unstructured":"Abhinav RP, Williams J, Livingston P, Anjana RM, Mohan V. Burden of diabetes and oral cancer in India. J Diabetes Complicat. 2020;34(11):107670. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107670.","journal-title":"J Diabetes Complicat"},{"key":"1926_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4103\/jod.jod_79_25","volume":"16","author":"RP Abhinav","year":"2025","unstructured":"Abhinav RP, Pradeepa R, Arunkumar MN, et al. Prevalence of type\u00a02 diabetes among oral cancer patients in a voluntary charitable cancer care center in South India. J Diabetol. 2025;16:358\u201365. https:\/\/doi.org\/10.4103\/jod.jod_79_25.","journal-title":"J Diabetol"},{"issue":"7","key":"1926_CR35","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.19070\/2377-8075-21000714","volume":"8","author":"RP Abhinav","year":"2021","unstructured":"Abhinav RP, Pradeepa R, Anjana RM, Mohan V. Importance of glycemic controlin individuals with type\u00a02 diabetes and oral cancer. Int J Dentistry Oral Sci. 2021;8(7):3497\u20139. https:\/\/doi.org\/10.19070\/2377-8075-21000714.","journal-title":"Int J Dentistry Oral Sci"},{"key":"1926_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105624","volume":"123","author":"M Madhulaxmi","year":"2021","unstructured":"Madhulaxmi M, Abhinav RP. Protein changes of WNT signaling pathway in oral cancer. Oral Oncol. 2021;123:105624. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105624.","journal-title":"Oral Oncol"},{"issue":"8","key":"1926_CR37","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.19070\/2377-8075-21000821","volume":"8","author":"RP Abhinav","year":"2021","unstructured":"Abhinav RP, Madhulaxmi M. Can insulin like growth factors be used as a biomarkers of oral cancer?-A systematic review. Int J Dentistry Oral Sci. 2021;8(8):4022\u20137. https:\/\/doi.org\/10.19070\/2377-8075-21000821.","journal-title":"Int J Dentistry Oral Sci"},{"issue":"2","key":"1926_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12663-024-02212-6","volume":"24","author":"RP Abhinav","year":"2025","unstructured":"Abhinav RP, Bennett CM, Anjana RM, et al. Expression of salivary and serum IGF-1 and IGFBP-3 in individuals with diabetes and oral cancer. J Maxillofac Oral Surg. 2025;24(2):432\u201340. https:\/\/doi.org\/10.1007\/s12663-024-02212-6.","journal-title":"J Maxillofac Oral Surg"},{"issue":"1","key":"1926_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-01755-x","volume":"9","author":"H Dong","year":"2024","unstructured":"Dong H, Sun Y, Nie L, et al. Metabolic memory: mechanisms and diseases. Signal Transduct Target Ther. 2024;9(1):38. https:\/\/doi.org\/10.1038\/s41392-024-01755-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1926_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1535370219826031","volume":"244","author":"JJ Moon","year":"2019","unstructured":"Moon JJ, Lu A, Moon C. Role of genomic instability in human carcinogenesis. Exp Biol Med (Maywood). 2019;244(3):227\u201340. https:\/\/doi.org\/10.1177\/1535370219826031.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1926_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184084","author":"A Bronowicka-Szyde\u0142ko","year":"2021","unstructured":"Bronowicka-Szyde\u0142ko A, Kotyra \u0141, Lewandowski \u0141, Gamian A, Kustrzeba-W\u00f3jcicka I. Role of advanced glycation end-products and other ligands for AGE receptors in thyroid cancer progression. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10184084.","journal-title":"J Clin Med"},{"key":"1926_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091402","author":"P Ramteke","year":"2019","unstructured":"Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091402.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1926_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/138920208785699580","volume":"9","author":"B Sadikovic","year":"2008","unstructured":"Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2008;9(6):394\u2013408. https:\/\/doi.org\/10.2174\/138920208785699580.","journal-title":"Curr Genomics"},{"issue":"5","key":"1926_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41419-022-04895-6","volume":"13","author":"D Sun","year":"2022","unstructured":"Sun D, Gan X, Liu L, et al. DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334. Cell Death Dis. 2022;13(5):446. https:\/\/doi.org\/10.1038\/s41419-022-04895-6.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1926_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231164548","volume":"51","author":"CE Kosmas","year":"2023","unstructured":"Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51(3):3000605231164548. https:\/\/doi.org\/10.1177\/03000605231164548.","journal-title":"J Int Med Res"},{"issue":"4","key":"1926_CR46","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4093\/dmj.2021.0131","volume":"45","author":"AMY Zhang","year":"2021","unstructured":"Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45(4):622. https:\/\/doi.org\/10.4093\/dmj.2021.0131.","journal-title":"Diabetes Metab J"},{"issue":"22","key":"1926_CR47","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/cells13221838","volume":"13","author":"M Mustafa","year":"2024","unstructured":"Mustafa M, Ahmad R, Tantry IQ, et al. Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. 2024;13(22):1838. https:\/\/doi.org\/10.3390\/cells13221838.","journal-title":"Cells"},{"issue":"4","key":"1926_CR48","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.metabol.2009.07.043","volume":"59","author":"DK Sanghera","year":"2010","unstructured":"Sanghera DK, Demirci FY, Been L, et al. PPARG and ADIPOQ gene polymorphisms increase type\u00a02 diabetes mellitus risk in Asian Indian Sikhs: Pro12Ala still remains as the strongest predictor. Metabolism. 2010;59(4):492\u2013501. https:\/\/doi.org\/10.1016\/j.metabol.2009.07.043.","journal-title":"Metabolism"},{"issue":"3","key":"1926_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.kint.2024.10.031","volume":"107","author":"I Mimura","year":"2025","unstructured":"Mimura I, Chen Z, Natarajan R. Epigenetic alterations and memory: key players in the development\/progression of chronic kidney disease promoted by acute kidney injury and diabetes. Kidney Int. 2025;107(3):434\u201356. https:\/\/doi.org\/10.1016\/j.kint.2024.10.031.","journal-title":"Kidney Int"},{"issue":"4","key":"1926_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jncc.2022.09.002","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Cent. 2022;2(4):277\u201390. https:\/\/doi.org\/10.1016\/j.jncc.2022.09.002.","journal-title":"J Natl Cancer Cent"},{"issue":"9","key":"1926_CR51","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1464-5491.2005.01616.x","volume":"22","author":"V Mohan","year":"2005","unstructured":"Mohan V, Gokulakrishnan K, Deepa R, Shanthirani CS, Datta M. Association of physical inactivity with components of metabolic syndrome and coronary artery disease\u2013the Chennai Urban Population Study (CUPS no 15). Diabet Med. 2005;22(9):1206\u201311. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01616.x.","journal-title":"Diabet Med"},{"key":"1926_CR52","doi-asserted-by":"publisher","unstructured":"Deepa R, Sandeep S, Mohan V. Abdominal obesity, visceral fat and type\u00a02 diabetes - \u201cAsian Indian phenotype\u201d. In: Mohan V, Rao GHR, editors. Type 2 diabetes in South Asians: epidemiology, risk factors and prevention. New Delhi: Jaypee; 2007. p. 138\u2013152. https:\/\/doi.org\/10.5005\/jp\/books\/10994_9.","DOI":"10.5005\/jp\/books\/10994_9"},{"key":"1926_CR53","doi-asserted-by":"publisher","first-page":"9051929","DOI":"10.1155\/2019\/9051929","volume":"2019","author":"J Lainampetch","year":"2019","unstructured":"Lainampetch J, Panprathip P, Phosat C, et al. Association of tumor necrosis factor alpha, interleukin 6, and C-reactive protein with the risk of developing type\u00a02 diabetes: a retrospective cohort study of rural Thais. J Diabetes Res. 2019;2019:9051929. https:\/\/doi.org\/10.1155\/2019\/9051929.","journal-title":"J Diabetes Res"},{"issue":"4","key":"1926_CR54","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1177\/193229681100500421","volume":"5","author":"K Indulekha","year":"2011","unstructured":"Indulekha K, Surendar J, Mohan V. High sensitivity C-reactive protein, tumor necrosis factor-\u03b1, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). J Diabetes Sci Technol. 2011;5(4):982\u20138. https:\/\/doi.org\/10.1177\/193229681100500421.","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"1926_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","volume":"21","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11\u20139. https:\/\/doi.org\/10.1016\/j.cytogfr.2009.11.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"1926_CR56","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016.","journal-title":"Cancer Cell"},{"issue":"17","key":"1926_CR57","doi-asserted-by":"publisher","first-page":"E4061","DOI":"10.1073\/pnas.1712345115","volume":"115","author":"B D\u00f6rsam","year":"2018","unstructured":"D\u00f6rsam B, Seiwert N, Foersch S, et al. PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. Proc Natl Acad Sci U S A. 2018;115(17):E4061-e4070. https:\/\/doi.org\/10.1073\/pnas.1712345115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt C","key":"1926_CR58","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.semcdb.2022.09.008","volume":"154","author":"S Rath","year":"2024","unstructured":"Rath S, Hawsawi YM, Alzahrani F, Khan MI. Epigenetic regulation of inflammation: the metabolomics connection. Semin Cell Dev Biol. 2024;154(Pt C):355\u201363. https:\/\/doi.org\/10.1016\/j.semcdb.2022.09.008.","journal-title":"Semin Cell Dev Biol"},{"key":"1926_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13148-016-0293-3","volume":"8","author":"C Sathishkumar","year":"2016","unstructured":"Sathishkumar C, Prabu P, Balakumar M, et al. Augmentation of histone deacetylase 3 (HDAC3) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type\u00a02 diabetes. Clin Epigenetics. 2016;8:125. https:\/\/doi.org\/10.1186\/s13148-016-0293-3.","journal-title":"Clin Epigenetics"},{"key":"1926_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.931493","volume":"10","author":"SYX Tan","year":"2022","unstructured":"Tan SYX, Zhang J, Tee WW. Epigenetic regulation of inflammatory signaling and inflammation-induced cancer. Front Cell Dev Biol. 2022;10:931493. https:\/\/doi.org\/10.3389\/fcell.2022.931493.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1926_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23(1):203. https:\/\/doi.org\/10.1186\/s12943-024-02119-3.","journal-title":"Mol Cancer"},{"key":"1926_CR62","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","volume":"107","author":"B Giri","year":"2018","unstructured":"Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother. 2018;107:306\u201328. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.157.","journal-title":"Biomed Pharmacother"},{"issue":"5930","key":"1926_CR63","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333. https:\/\/doi.org\/10.1126\/science.1160809.","journal-title":"Science"},{"key":"1926_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710037","author":"A Fukushi","year":"2022","unstructured":"Fukushi A, Kim HD, Chang YC, Kim CH. Revisited metabolic control and reprogramming cancers by means of the Warburg effect in tumor cells. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231710037.","journal-title":"Int J Mol Sci"},{"issue":"SI","key":"1926_CR65","first-page":"109","volume":"23","author":"E Sanders","year":"2012","unstructured":"Sanders E. Pseudohypoxia, mitochondrial mutations, the Warburg effect, and cancer. Biomed Res. 2012;23(SI):109\u201331.","journal-title":"Biomed Res"},{"key":"1926_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1202093","volume":"13","author":"C Iacobini","year":"2023","unstructured":"Iacobini C, Vitale M, Pugliese G, Menini S. The \u201csweet\u201d path to cancer: focus on cellular glucose metabolism. Front Oncol. 2023;13:1202093. https:\/\/doi.org\/10.3389\/fonc.2023.1202093.","journal-title":"Front Oncol"},{"issue":"Suppl 2","key":"1926_CR67","first-page":"2s26","volume":"25","author":"K Kankova","year":"2012","unstructured":"Kankova K, Hrstka R. Cancer as a metabolic disease and diabetes as a cancer risk? Klin Onkol. 2012;25(Suppl 2):2s26-31.","journal-title":"Klin Onkol"},{"key":"1926_CR68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000152029","volume":"19","author":"JB LaValle","year":"2008","unstructured":"LaValle JB. Nutrition, diabetes, and cancer. Diabetes Cancer Epidemiol Evidence Mole Links. 2008;19:114. https:\/\/doi.org\/10.1159\/000152029.","journal-title":"Diabetes Cancer Epidemiol Evidence Mole Links"},{"key":"1926_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122755","author":"JS Burns","year":"2017","unstructured":"Burns JS, Manda G. Metabolic pathways of the Warburg effect in health and disease: perspectives of choice, chain or chance. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18122755.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1926_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1159\/000493028","volume":"49","author":"J Pang","year":"2018","unstructured":"Pang J, Cui J, Xi C, et al. Inhibition of poly(ADP-ribose) polymerase increased lipid accumulation through SREBP1 modulation. Cell Physiol Biochem. 2018;49(2):645\u201352. https:\/\/doi.org\/10.1159\/000493028.","journal-title":"Cell Physiol Biochem"},{"issue":"5\u20136","key":"1926_CR71","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1101\/gad.334284.119","volume":"34","author":"M Sz\u00e1nt\u00f3","year":"2020","unstructured":"Sz\u00e1nt\u00f3 M, Bai P. The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism. Genes Dev. 2020;34(5\u20136):321\u201340. https:\/\/doi.org\/10.1101\/gad.334284.119.","journal-title":"Genes Dev"},{"key":"1926_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.793428","volume":"9","author":"M Huo","year":"2021","unstructured":"Huo M, Zhang J, Huang W, Wang Y. Interplay among metabolism, epigenetic modifications, and gene expression in cancer. Front Cell Dev Biol. 2021;9:793428. https:\/\/doi.org\/10.3389\/fcell.2021.793428.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1926_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13072-024-00554-6","volume":"17","author":"R Prabhakaran","year":"2024","unstructured":"Prabhakaran R, Thamarai R, Sivasamy S, et al. Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy. Epigenetics Chromatin. 2024;17(1):31. https:\/\/doi.org\/10.1186\/s13072-024-00554-6.","journal-title":"Epigenetics Chromatin"},{"issue":"8","key":"1926_CR74","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487\u2013500. https:\/\/doi.org\/10.1038\/nrg.2016.59.","journal-title":"Nat Rev Genet"},{"key":"1926_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/bs.acr.2024.05.007","volume":"161","author":"J Mishra","year":"2024","unstructured":"Mishra J, Chakraborty S, Nandi P, et al. Epigenetic regulation of androgen dependent and independent prostate cancer. Adv Cancer Res. 2024;161:223\u2013320. https:\/\/doi.org\/10.1016\/bs.acr.2024.05.007.","journal-title":"Adv Cancer Res"},{"issue":"3","key":"1926_CR76","doi-asserted-by":"publisher","first-page":"e30531","DOI":"10.1002\/jcb.30531","volume":"125","author":"J Mishra","year":"2024","unstructured":"Mishra J, Chakraborty S, Roy NA, et al. Mechanotransduction and epigenetic modulations of chromatin: Role of mechanical signals in gene regulation. J Cell Biochem. 2024;125(3):e30531. https:\/\/doi.org\/10.1002\/jcb.30531.","journal-title":"J Cell Biochem"},{"key":"1926_CR77","doi-asserted-by":"publisher","first-page":"216779","DOI":"10.1016\/j.canlet.2024.216779","volume":"587","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty S, Nandi P, Mishra J, et al. Molecular mechanisms in regulation of autophagy and apoptosis in view of epigenetic regulation of genes and involvement of liquid-liquid phase separation. Cancer Lett. 2024;587:216779. https:\/\/doi.org\/10.1016\/j.canlet.2024.216779.","journal-title":"Cancer Lett"},{"key":"1926_CR78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2020.05.017","volume":"72","author":"D Sengupta","year":"2021","unstructured":"Sengupta D, Deb M, Kar S, et al. Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention. Semin Cancer Biol. 2021;72:46\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2020.05.017.","journal-title":"Semin Cancer Biol"},{"key":"1926_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097848","author":"IV Bure","year":"2023","unstructured":"Bure IV, Nemtsova MV. Mutual regulation of ncRNAs and chromatin remodeling complexes in normal and pathological conditions. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24097848.","journal-title":"Int J Mol Sci"},{"key":"1926_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101956","volume":"88","author":"F Galkin","year":"2023","unstructured":"Galkin F, Kovalchuk O, Koldasbayeva D, Zhavoronkov A, Bischof E. Stress, diet, exercise: common environmental factors and their impact on epigenetic age. Ageing Res Rev. 2023;88:101956. https:\/\/doi.org\/10.1016\/j.arr.2023.101956.","journal-title":"Ageing Res Rev"},{"issue":"11","key":"1926_CR81","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/jama.2015.10414","volume":"314","author":"AP Feinberg","year":"2015","unstructured":"Feinberg AP, Fallin MD. Epigenetics at the crossroads of genes and the environment. JAMA. 2015;314(11):1129\u201330. https:\/\/doi.org\/10.1001\/jama.2015.10414.","journal-title":"JAMA"},{"key":"1926_CR82","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-61779-612-8_23","volume":"863","author":"U Lim","year":"2012","unstructured":"Lim U, Song MA. Dietary and lifestyle factors of DNA methylation. Methods Mol Biol. 2012;863:359\u201376. https:\/\/doi.org\/10.1007\/978-1-61779-612-8_23.","journal-title":"Methods Mol Biol"},{"key":"1926_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58010016","author":"MR Hayden","year":"2021","unstructured":"Hayden MR, Tyagi SC. Impaired folate-mediated one-carbon metabolism in type\u00a02 diabetes, late-onset Alzheimer\u2019s disease and long COVID. Medicina (Kaunas). 2021. https:\/\/doi.org\/10.3390\/medicina58010016.","journal-title":"Medicina (Kaunas)"},{"issue":"9","key":"1926_CR84","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/circresaha.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058\u201370. https:\/\/doi.org\/10.1161\/circresaha.110.223545.","journal-title":"Circ Res"},{"key":"1926_CR85","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqad080","author":"J Xiong","year":"2023","unstructured":"Xiong J, Yan C, Zhang Q, Zhang J. \u03b1-Ketoglutarate-dependent enzymes in breast cancer and therapeutic implications. Endocrinology. 2023. https:\/\/doi.org\/10.1210\/endocr\/bqad080.","journal-title":"Endocrinology"},{"issue":"12_Supplement","key":"1926_CR86","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1158\/1538-7445.AM2022-3766","volume":"82","author":"JD Kindrick","year":"2022","unstructured":"Kindrick JD, Ratcliffe PJ, Figg WD, Mole DR. Abstract 3766: correlating locus-specific changes in histone trimethylation and gene expression in hypoxia. Cancer Res. 2022;82(12_Supplement):3766\u20133766. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-3766.","journal-title":"Cancer Res"},{"issue":"45","key":"1926_CR87","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1556\/650.2019.31533","volume":"160","author":"K Jenei","year":"2019","unstructured":"Jenei K, Szatm\u00e1ri I, Szab\u00f3 E, et al. Changes of lactate levels in diabetic ketoacidosis and in newly diagnosed type\u00a01 diabetes mellitus. Orv Hetil. 2019;160(45):1784\u201390. https:\/\/doi.org\/10.1556\/650.2019.31533.","journal-title":"Orv Hetil"},{"issue":"6","key":"1926_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102303","volume":"9","author":"Q Hao","year":"2022","unstructured":"Hao Q, Huang Z, Li Q, et al. A novel metabolic reprogramming strategy for the treatment of diabetes-associated breast cancer. Adv Sci (Weinh). 2022;9(6):e2102303. https:\/\/doi.org\/10.1002\/advs.202102303.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"1926_CR89","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","volume":"49","author":"S Reuter","year":"2010","unstructured":"Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603\u201316. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.09.006.","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"1926_CR90","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/0008-5472.Can-19-0924","volume":"80","author":"M Yu","year":"2020","unstructured":"Yu M, Hazelton WD, Luebeck GE, Grady WM. Epigenetic aging: more than just a clock when it comes to cancer. Cancer Res. 2020;80(3):367\u201374. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-0924.","journal-title":"Cancer Res"},{"key":"1926_CR91","doi-asserted-by":"publisher","first-page":"847629","DOI":"10.3389\/fbinf.2022.847629","volume":"2","author":"L Chen","year":"2022","unstructured":"Chen L, Ganz PA, Sehl ME. DNA methylation, aging, and cancer risk: a mini-review. Front Bioinform. 2022;2:847629. https:\/\/doi.org\/10.3389\/fbinf.2022.847629.","journal-title":"Front Bioinform"},{"issue":"6","key":"1926_CR92","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s11357-022-00626-z","volume":"44","author":"E Fraszczyk","year":"2022","unstructured":"Fraszczyk E, Thio CHL, Wackers P, et al. DNA methylation trajectories and accelerated epigenetic aging in incident type\u00a02 diabetes. Geroscience. 2022;44(6):2671\u201384. https:\/\/doi.org\/10.1007\/s11357-022-00626-z.","journal-title":"Geroscience"},{"issue":"6","key":"1926_CR93","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41366-024-01466-x","volume":"48","author":"T F\u00f6hr","year":"2024","unstructured":"F\u00f6hr T, Hendrix A, Kankaanp\u00e4\u00e4 A, et al. Metabolic syndrome and epigenetic aging: a twin study. Int J Obes (Lond). 2024;48(6):778\u201387. https:\/\/doi.org\/10.1038\/s41366-024-01466-x.","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"1926_CR94","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13148-019-0767-1","volume":"11","author":"DR Nannini","year":"2019","unstructured":"Nannini DR, Joyce BT, Zheng Y, et al. Epigenetic age acceleration and metabolic syndrome in the coronary artery risk development in young adults study. Clin Epigenetics. 2019;11(1):160. https:\/\/doi.org\/10.1186\/s13148-019-0767-1.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1926_CR95","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/jci69735","volume":"124","author":"JP Issa","year":"2014","unstructured":"Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest. 2014;124(1):24\u20139. https:\/\/doi.org\/10.1172\/jci69735.","journal-title":"J Clin Invest"},{"issue":"11","key":"1926_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001551","volume":"10","author":"A Jones","year":"2013","unstructured":"Jones A, Teschendorff AE, Li Q, et al. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med. 2013;10(11):e1001551. https:\/\/doi.org\/10.1371\/journal.pmed.1001551.","journal-title":"PLoS Med"},{"key":"1926_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0409-4","volume":"9","author":"EG Luebeck","year":"2017","unstructured":"Luebeck EG, Curtius K, Hazelton WD, et al. Identification of a key role of widespread epigenetic drift in Barrett\u2019s esophagus and esophageal adenocarcinoma. Clin Epigenetics. 2017;9:113. https:\/\/doi.org\/10.1186\/s13148-017-0409-4.","journal-title":"Clin Epigenetics"},{"key":"1926_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.955835","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Bao L, Zhu P, Wang S. Effect of metformin on the epigenetic age of peripheral blood in patients with diabetes mellitus. Front Genet. 2022;13:955835. https:\/\/doi.org\/10.3389\/fgene.2022.955835.","journal-title":"Front Genet"},{"issue":"4","key":"1926_CR99","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1289\/ehp.8700","volume":"114","author":"DC Dolinoy","year":"2006","unstructured":"Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ Health Perspect. 2006;114(4):567\u201372. https:\/\/doi.org\/10.1289\/ehp.8700.","journal-title":"Environ Health Perspect"},{"issue":"1","key":"1926_CR100","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12934-020-01330-3","volume":"19","author":"K Kesh","year":"2020","unstructured":"Kesh K, Mendez R, Abdelrahman L, Banerjee S, Banerjee S. Type\u00a02 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma. Microb Cell Fact. 2020;19(1):75. https:\/\/doi.org\/10.1186\/s12934-020-01330-3.","journal-title":"Microb Cell Fact"},{"issue":"Pt 3","key":"1926_CR101","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semcancer.2021.06.024","volume":"86","author":"S Haque","year":"2022","unstructured":"Haque S, Raina R, Afroze N, et al. Microbial dysbiosis and epigenetics modulation in cancer development - a chemopreventive approach. Semin Cancer Biol. 2022;86(Pt 3):666\u201381. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.024.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1926_CR102","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1210\/jc.2015-4251","volume":"101","author":"KM Utzschneider","year":"2016","unstructured":"Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms linking the gut microbiome and glucose metabolism. J Clin Endocrinol Metab. 2016;101(4):1445\u201354. https:\/\/doi.org\/10.1210\/jc.2015-4251.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"1926_CR103","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11010-013-1911-4","volume":"388","author":"B Jayashree","year":"2014","unstructured":"Jayashree B, Bibin YS, Prabhu D, et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type\u00a02 diabetes. Mol Cell Biochem. 2014;388(1\u20132):203\u201310. https:\/\/doi.org\/10.1007\/s11010-013-1911-4.","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"1926_CR104","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/dme.12360","volume":"31","author":"F Horton","year":"2014","unstructured":"Horton F, Wright J, Smith L, Hinton PJ, Robertson MD. Increased intestinal permeability to oral chromium (51Cr)-EDTA in human type\u00a02 diabetes. Diabet Med. 2014;31(5):559\u201363. https:\/\/doi.org\/10.1111\/dme.12360.","journal-title":"Diabet Med"},{"issue":"5","key":"1926_CR105","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/acs.chemrestox.9b00015","volume":"32","author":"CL Seiler","year":"2019","unstructured":"Seiler CL, Song JM, Fernandez J, et al. Epigenetic changes in alveolar type\u00a0II lung cells of A\/J mice following intranasal treatment with lipopolysaccharide. Chem Res Toxicol. 2019;32(5):831\u20139. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00015.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"1926_CR106","doi-asserted-by":"publisher","first-page":"72","DOI":"10.30476\/mejc.2019.81423.1001","volume":"11","author":"S Tavakolian","year":"2020","unstructured":"Tavakolian S, Goudarzi H, Faghihloo E. LPS induces microRNAs -9, -192, and -205 overexpression in colorectal cell lines SW480, HCT116. Middle East J Cancer. 2020;11(1):72\u20139. https:\/\/doi.org\/10.30476\/mejc.2019.81423.1001.","journal-title":"Middle East J Cancer"},{"key":"1926_CR107","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.2147\/jir.S332943","volume":"14","author":"S Tang","year":"2021","unstructured":"Tang S, Lian X, Cheng H, et al. Bacterial lipopolysaccharide augmented malignant transformation and promoted the stemness in prostate cancer epithelial cells. J Inflamm Res. 2021;14:5849\u201362. https:\/\/doi.org\/10.2147\/jir.S332943.","journal-title":"J Inflamm Res"},{"key":"1926_CR108","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S2213-8587(15)00127-8","volume":"3","author":"JC Chambers","year":"2015","unstructured":"Chambers JC, Loh M, Lehne B, et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type\u00a02 diabetes: a nested case-control study. Lancet Diabetes Endocrinol. 2015;3:526\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1926_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004160","volume":"10","author":"T Dayeh","year":"2014","unstructured":"Dayeh T, Volkov P, Sal\u00f6 S, et al. Genome-wide DNA methylation analysis of human pancreatic islets from type\u00a02 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion. PLoS Genet. 2014;10(3):e1004160. https:\/\/doi.org\/10.1371\/journal.pgen.1004160.","journal-title":"PLoS Genet"},{"key":"1926_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00744","volume":"9","author":"T Willmer","year":"2018","unstructured":"Willmer T, Johnson R, Louw J, Pheiffer C. Blood-based DNA methylation biomarkers for type\u00a02 diabetes: potential for clinical applications. Front Endocrinol (Lausanne). 2018;9:744. https:\/\/doi.org\/10.3389\/fendo.2018.00744.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1926_CR111","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2337\/db18-0537","volume":"67","author":"ED Rosen","year":"2018","unstructured":"Rosen ED, Kaestner KH, Natarajan R, et al. Epigenetics and epigenomics: implications for diabetes and obesity. Diabetes. 2018;67(10):1923\u201331. https:\/\/doi.org\/10.2337\/db18-0537.","journal-title":"Diabetes"},{"key":"1926_CR112","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2050-7771-2-19","volume":"2","author":"PJ Mishra","year":"2014","unstructured":"Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics. Biomark Res. 2014;2:19. https:\/\/doi.org\/10.1186\/2050-7771-2-19.","journal-title":"Biomark Res"},{"issue":"1","key":"1926_CR113","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12935-024-03386-2","volume":"24","author":"V Hazari","year":"2024","unstructured":"Hazari V, Samali SA, Izadpanahi P, Mollaei H, Sadri F, Rezaei Z. MicroRNA-98: the multifaceted regulator in human cancer progression and therapy. Cancer Cell Int. 2024;24(1):209. https:\/\/doi.org\/10.1186\/s12935-024-03386-2.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1926_CR114","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11033-024-10197-1","volume":"52","author":"Z Latifi","year":"2024","unstructured":"Latifi Z, Nikanfar S, Khodavirdilou R, et al. MicroRNAs as diagnostic biomarkers in diabetes male infertility: a systematic review. Mol Biol Rep. 2024;52(1):90. https:\/\/doi.org\/10.1007\/s11033-024-10197-1.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1926_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01988-0","volume":"22","author":"M Nemecz","year":"2023","unstructured":"Nemecz M, Stefan DS, Comari\u0163a IK, et al. Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155\u00a0have biomarker potential. Cardiovasc Diabetol. 2023;22(1):260. https:\/\/doi.org\/10.1186\/s12933-023-01988-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1926_CR116","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.2337\/db12-0963","volume":"62","author":"YH Chen","year":"2013","unstructured":"Chen YH, Heneidi S, Lee JM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 2013;62(7):2278\u201386. https:\/\/doi.org\/10.2337\/db12-0963.","journal-title":"Diabetes"},{"issue":"1-2","key":"1926_CR117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11010-014-2170-8","volume":"397","author":"ST Yan","year":"2014","unstructured":"Yan ST, Li CL, Tian H, et al. MiR-199a is overexpressed in plasma of type\u00a02 diabetes patients which contributes to type\u00a02 diabetes by targeting GLUT4. Mol Cell Biochem. 2014;397(1\u20132):45\u201351. https:\/\/doi.org\/10.1007\/s11010-014-2170-8.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"1926_CR118","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","volume":"43","author":"EB Geer","year":"2014","unstructured":"Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am. 2014;43(1):75\u2013102. https:\/\/doi.org\/10.1016\/j.ecl.2013.10.005.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"1926_CR119","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabres.2015.09.014","volume":"110","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B, Cariou B. MTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015;110(2):101\u20138. https:\/\/doi.org\/10.1016\/j.diabres.2015.09.014.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1926_CR120","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/med.0000000000000546","volume":"27","author":"HK Akturk","year":"2020","unstructured":"Akturk HK, Michels AW. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2020;27(4):187\u201393. https:\/\/doi.org\/10.1097\/med.0000000000000546.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1926_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1355171","volume":"15","author":"T Mugiya","year":"2024","unstructured":"Mugiya T, Mothibe M, Khathi A, Ngubane P, Sibiya N. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review. Front Pharmacol. 2024;15:1355171. https:\/\/doi.org\/10.3389\/fphar.2024.1355171.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1926_CR122","doi-asserted-by":"publisher","first-page":"27","DOI":"10.32607\/20758251-2015-7-3-27-37","volume":"7","author":"NV Malyuchenko","year":"2015","unstructured":"Malyuchenko NV, Kotova EY, Kulaeva OI, Kirpichnikov MP, Studitskiy VM. PARP1 inhibitors: antitumor drug design. Acta Naturae. 2015;7(3):27\u201337.","journal-title":"Acta Naturae"},{"key":"1926_CR123","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.2147\/ott.S139336","volume":"10","author":"A Ohmoto","year":"2017","unstructured":"Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther. 2017;10:5195\u2013208. https:\/\/doi.org\/10.2147\/ott.S139336.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"1926_CR124","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.2337\/db06-0147","volume":"55","author":"C Szab\u00f3","year":"2006","unstructured":"Szab\u00f3 C, Biser A, Benko R, B\u00f6ttinger E, Suszt\u00e1k K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type\u00a02 diabetic Leprdb\/db mice. Diabetes. 2006;55(11):3004\u201312. https:\/\/doi.org\/10.2337\/db06-0147.","journal-title":"Diabetes"},{"issue":"1\u20132","key":"1926_CR125","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yexcr.2018.10.003","volume":"373","author":"M Waldman","year":"2018","unstructured":"Waldman M, Nudelman V, Shainberg A, et al. PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1\u03b1 axis. Exp Cell Res. 2018;373(1\u20132):112\u20138. https:\/\/doi.org\/10.1016\/j.yexcr.2018.10.003.","journal-title":"Exp Cell Res"},{"issue":"165","key":"1926_CR126","first-page":"13","volume":"32","author":"J Sun","year":"2021","unstructured":"Sun J, Chen L, Chen R, Lou Q, Wang H. Poly(ADP-ribose) polymerase-1: an update on its role in diabetic retinopathy. Discov Med. 2021;32(165):13\u201322.","journal-title":"Discov Med"},{"issue":"6","key":"1926_CR127","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00210-017-1360-9","volume":"390","author":"EM Zakaria","year":"2017","unstructured":"Zakaria EM, El-Maraghy NN, Ahmed AF, Ali AA, El-Bassossy HM. PARP inhibition ameliorates nephropathy in an animal model of type\u00a02 diabetes: focus on oxidative stress, inflammation, and fibrosis. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(6):621\u201331. https:\/\/doi.org\/10.1007\/s00210-017-1360-9.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"1926_CR128","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/hypertensionaha.111.190140","volume":"59","author":"SK Choi","year":"2012","unstructured":"Choi SK, Gal\u00e1n M, Kassan M, Partyka M, Trebak M, Matrougui K. Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type\u00a02 diabetes mellitus. Hypertension. 2012;59(5):1060\u20138. https:\/\/doi.org\/10.1161\/hypertensionaha.111.190140.","journal-title":"Hypertension"},{"issue":"4","key":"1926_CR129","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdi.12472","volume":"7","author":"H Wang","year":"2016","unstructured":"Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is associated with diabetes: evidence from meta-analysis. J Diabetes Investig. 2016;7(4):629\u201336. https:\/\/doi.org\/10.1111\/jdi.12472.","journal-title":"J Diabetes Investig"},{"issue":"8","key":"1926_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02247","volume":"5","author":"YC Yadav","year":"2019","unstructured":"Yadav YC. Effect of cisplatin on pancreas and testies in Wistar rats: biochemical parameters and histology. Heliyon. 2019;5(8):e02247. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02247.","journal-title":"Heliyon"},{"issue":"1","key":"1926_CR131","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.3747\/co.26.4151","volume":"26","author":"V Venetsanaki","year":"2019","unstructured":"Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr Oncol. 2019;26(1):e111\u20134. https:\/\/doi.org\/10.3747\/co.26.4151.","journal-title":"Curr Oncol"},{"issue":"11","key":"1926_CR132","first-page":"5625","volume":"11","author":"MS Misirkic Marjanovic","year":"2021","unstructured":"Misirkic Marjanovic MS, Vucicevic LM, Despotovic AR, Stamenkovic MM, Janjetovic KD. Dual anticancer role of metformin: an old drug regulating AMPK dependent\/independent pathways in metabolic, oncogenic\/tumorsuppresing and immunity context. Am J Cancer Res. 2021;11(11):5625\u201343.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"1926_CR133","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10552-012-9971-4","volume":"23","author":"AA Onitilo","year":"2012","unstructured":"Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23(7):991\u20131008. https:\/\/doi.org\/10.1007\/s10552-012-9971-4.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"1926_CR134","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","volume":"137","author":"D Li","year":"2009","unstructured":"Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2009.04.013.","journal-title":"Gastroenterology"},{"issue":"4","key":"1926_CR135","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/cam4.1354","volume":"7","author":"H Tang","year":"2018","unstructured":"Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018;7(4):1070\u201380. https:\/\/doi.org\/10.1002\/cam4.1354.","journal-title":"Cancer Med"},{"key":"1926_CR136","first-page":"68","volume":"60","author":"V Mohan","year":"2012","unstructured":"Mohan V, Bedi S, Unnikrishnan R, Sahay BK, Joshpi S, Misra A. Pioglitazone\u2013where do we stand in India? J Assoc Physicians India. 2012;60:68\u201370.","journal-title":"J Assoc Physicians India"},{"key":"1926_CR137","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1541","volume":"352","author":"M Tuccori","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541. https:\/\/doi.org\/10.1136\/bmj.i1541.","journal-title":"BMJ"},{"issue":"3","key":"1926_CR138","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265\u201377. https:\/\/doi.org\/10.1001\/jama.2015.7996.","journal-title":"JAMA"},{"issue":"5","key":"1926_CR139","doi-asserted-by":"publisher","first-page":"639","DOI":"10.4103\/2230-8210.163187","volume":"19","author":"S Gupta","year":"2015","unstructured":"Gupta S, Gupta K, Ravi R, et al. Pioglitazone and the risk of bladder cancer: an Indian retrospective cohort study. Indian J Endocrinol Metab. 2015;19(5):639\u201343. https:\/\/doi.org\/10.4103\/2230-8210.163187.","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"1926_CR140","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4239\/wjd.v13.i2.85","volume":"13","author":"M Florentin","year":"2022","unstructured":"Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes. 2022;13(2):85\u201396. https:\/\/doi.org\/10.4239\/wjd.v13.i2.85.","journal-title":"World J Diabetes"},{"key":"1926_CR141","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0530","author":"AE Espinosa De Ycaza","year":"2024","unstructured":"Espinosa De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N. Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review. Thyroid. 2024. https:\/\/doi.org\/10.1089\/thy.2023.0530.","journal-title":"Thyroid"},{"key":"1926_CR142","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62. https:\/\/doi.org\/10.1038\/s41392-019-0095-0.","journal-title":"Signal Transduct Target Ther"},{"key":"1926_CR143","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20202160","author":"R Singh","year":"2020","unstructured":"Singh R, Chandel S, Dey D, et al. Epigenetic modification and therapeutic targets of diabetes mellitus. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/bsr20202160.","journal-title":"Biosci Rep"},{"key":"1926_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.576946","volume":"8","author":"G Li","year":"2020","unstructured":"Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946. https:\/\/doi.org\/10.3389\/fcell.2020.576946.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"1926_CR145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135410","volume":"10","author":"N Nalabothula","year":"2015","unstructured":"Nalabothula N, Al-jumaily T, Eteleeb AM, et al. Genome-wide profiling of PARP1 reveals an interplay with gene regulatory regions and DNA methylation. PLoS ONE. 2015;10(8):e0135410. https:\/\/doi.org\/10.1371\/journal.pone.0135410.","journal-title":"PLoS ONE"},{"issue":"3","key":"1926_CR146","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.diabet.2018.08.004","volume":"45","author":"P Prabu","year":"2019","unstructured":"Prabu P, Rome S, Sathishkumar C, et al. MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type\u00a02 diabetes patients with the \u201cAsian Indian phenotype.\u201d Diabetes Metab. 2019;45(3):276\u201385. https:\/\/doi.org\/10.1016\/j.diabet.2018.08.004.","journal-title":"Diabetes Metab"},{"issue":"7","key":"1926_CR147","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00592-020-01486-9","volume":"57","author":"P Prabu","year":"2020","unstructured":"Prabu P, Poongothai S, Shanthirani CS, Anjana RM, Mohan V, Balasubramanyam M. Altered circulatory levels of miR-128, BDNF, cortisol and shortened telomeres in patients with type\u00a02 diabetes and depression. Acta Diabetol. 2020;57(7):799\u2013807. https:\/\/doi.org\/10.1007\/s00592-020-01486-9.","journal-title":"Acta Diabetol"},{"issue":"3","key":"1926_CR148","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.drudis.2015.12.001","volume":"21","author":"AO Arguelles","year":"2016","unstructured":"Arguelles AO, Meruvu S, Bowman JD, Choudhury M. Are epigenetic drugs for diabetes and obesity at our door step? Drug Discov Today. 2016;21(3):499\u2013509. https:\/\/doi.org\/10.1016\/j.drudis.2015.12.001.","journal-title":"Drug Discov Today"},{"issue":"8","key":"1926_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108545","volume":"37","author":"TA PramodKumar","year":"2023","unstructured":"PramodKumar TA, Sivaprasad S, Venkatesan U, et al. Role of cystatin C in the detection of sight-threatening diabetic retinopathy in Asian Indians with type\u00a02 diabetes. J Diabetes Complicat. 2023;37(8):108545. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108545.","journal-title":"J Diabetes Complicat"},{"key":"1926_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbi.2014.02.001","volume":"213","author":"S Khan","year":"2014","unstructured":"Khan S, Jena GB. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38\/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat. Chem Biol Interact. 2014;213:1\u201312. https:\/\/doi.org\/10.1016\/j.cbi.2014.02.001.","journal-title":"Chem Biol Interact"},{"issue":"5-6","key":"1926_CR151","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2119\/molmed.2011.00021","volume":"17","author":"DP Christensen","year":"2011","unstructured":"Christensen DP, Dahll\u00f6f M, Lundh M, et al. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med. 2011;17(5\u20136):378\u201390. https:\/\/doi.org\/10.2119\/molmed.2011.00021.","journal-title":"Mol Med"},{"issue":"4","key":"1926_CR152","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2337\/dc19-1828","volume":"43","author":"C Ochoa-Rosales","year":"2020","unstructured":"Ochoa-Rosales C, Portilla-Fernandez E, Nano J, et al. Epigenetic link between statin therapy and type\u00a02 diabetes. Diabetes Care. 2020;43(4):875\u201384. https:\/\/doi.org\/10.2337\/dc19-1828.","journal-title":"Diabetes Care"},{"issue":"2","key":"1926_CR153","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2011.12.001","volume":"142","author":"BD White","year":"2012","unstructured":"White BD, Chien AJ, Dawson DW. Dysregulation of Wnt\/\u03b2-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2011.12.001.","journal-title":"Gastroenterology"},{"issue":"1","key":"1926_CR154","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1530\/jme-13-0152","volume":"52","author":"C Garc\u00eda-Jim\u00e9nez","year":"2014","unstructured":"Garc\u00eda-Jim\u00e9nez C, Garc\u00eda-Mart\u00ednez JM, Chocarro-Calvo A, De la Vieja A. A new link between diabetes and cancer: enhanced WNT\/\u03b2-catenin signaling by high glucose. J Mol Endocrinol. 2014;52(1):R51-66. https:\/\/doi.org\/10.1530\/jme-13-0152.","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"1926_CR155","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s0301-0082(01)00011-9","volume":"65","author":"CA Grimes","year":"2001","unstructured":"Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001;65(4):391\u2013426. https:\/\/doi.org\/10.1016\/s0301-0082(01)00011-9.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"1926_CR156","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/med.10011","volume":"22","author":"A Martinez","year":"2002","unstructured":"Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 2002;22(4):373\u201384. https:\/\/doi.org\/10.1002\/med.10011.","journal-title":"Med Res Rev"},{"issue":"20","key":"1926_CR157","doi-asserted-by":"publisher","first-page":"14225","DOI":"10.1074\/jbc.M113.527671","volume":"289","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li G, Mao F, et al. Ras-induced epigenetic inactivation of the RRAD (Ras-related associated with diabetes) gene promotes glucose uptake in a human ovarian cancer model. J Biol Chem. 2014;289(20):14225\u201338. https:\/\/doi.org\/10.1074\/jbc.M113.527671.","journal-title":"J Biol Chem"},{"issue":"7586","key":"1926_CR158","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413\u20137. https:\/\/doi.org\/10.1038\/nature16508.","journal-title":"Nature"},{"issue":"10","key":"1926_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30986","volume":"10","author":"J Wang","year":"2024","unstructured":"Wang J, Wang X, Liu Z, Li S, Yin W. IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells. Heliyon. 2024;10(10):e30986. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30986.","journal-title":"Heliyon"},{"key":"1926_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153965","author":"Z Hong","year":"2023","unstructured":"Hong Z, Xie W, Zhuo H, et al. Crosstalk between cancer cells and cancer-associated fibroblasts mediated by TGF-\u03b21-IGFBP7 signaling promotes the progression of infiltrative gastric cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153965.","journal-title":"Cancers (Basel)"},{"key":"1926_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898493","volume":"13","author":"X Yi","year":"2022","unstructured":"Yi X, Zheng X, Xu H, et al. IGFBP7 and the tumor immune landscape: a novel target for immunotherapy in bladder cancer. Front Immunol. 2022;13:898493. https:\/\/doi.org\/10.3389\/fimmu.2022.898493.","journal-title":"Front Immunol"},{"key":"1926_CR162","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7827-6-54","volume":"6","author":"M Kutsukake","year":"2008","unstructured":"Kutsukake M, Ishihara R, Momose K, et al. Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis. Reprod Biol Endocrinol. 2008;6:54. https:\/\/doi.org\/10.1186\/1477-7827-6-54.","journal-title":"Reprod Biol Endocrinol"},{"key":"1926_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115732","volume":"215","author":"R Giordo","year":"2023","unstructured":"Giordo R, Posadino AM, Mangoni AA, Pintus G. Metformin-mediated epigenetic modifications in diabetes and associated conditions: biological and clinical relevance. Biochem Pharmacol. 2023;215:115732. https:\/\/doi.org\/10.1016\/j.bcp.2023.115732.","journal-title":"Biochem Pharmacol"},{"key":"1926_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137476","author":"M Pliszka","year":"2024","unstructured":"Pliszka M, Szablewski L. Associations between diabetes mellitus and selected cancers. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25137476.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1926_CR165","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4239\/wjd.v5.i3.372","volume":"5","author":"CX Xu","year":"2014","unstructured":"Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J Diabetes. 2014;5(3):372\u201380. https:\/\/doi.org\/10.4239\/wjd.v5.i3.372.","journal-title":"World J Diabetes"},{"issue":"7","key":"1926_CR166","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jcjd.2020.08.048","volume":"44","author":"SS Chen","year":"2020","unstructured":"Chen SS, Nadarajah A, Wang K-W, et al. 42 - The prevalence of diabetes mellitus in childhood cancer survivors: a systematic review and meta-analysis. Can J Diabetes. 2020;44(7):S19. https:\/\/doi.org\/10.1016\/j.jcjd.2020.08.048.","journal-title":"Can J Diabetes"},{"issue":"4","key":"1926_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100218","volume":"6","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Wang H, Tang Y, et al. Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies. ESMO Open. 2021;6(4):100218. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100218.","journal-title":"ESMO Open"},{"issue":"1","key":"1926_CR168","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/107327480701400103","volume":"14","author":"M Extermann","year":"2007","unstructured":"Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14(1):13\u201322. https:\/\/doi.org\/10.1177\/107327480701400103.","journal-title":"Cancer Control"},{"issue":"10","key":"1926_CR169","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s1470-2045(12)70323-6","volume":"13","author":"F de Vathaire","year":"2012","unstructured":"de Vathaire F, El-Fayech C, Ben Ayed FF, et al. Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol. 2012;13(10):1002\u201310. https:\/\/doi.org\/10.1016\/s1470-2045(12)70323-6.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1926_CR170","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/db16-1477","volume":"66","author":"DK Andersen","year":"2017","unstructured":"Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66(5):1103\u201310. https:\/\/doi.org\/10.2337\/db16-1477.","journal-title":"Diabetes"},{"issue":"2","key":"1926_CR171","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000495698","volume":"91","author":"DN Friedman","year":"2019","unstructured":"Friedman DN, Tonorezos ES, Cohen P. Diabetes and metabolic syndrome in survivors of childhood cancer. Horm Res Paediatr. 2019;91(2):118\u201327. https:\/\/doi.org\/10.1159\/000495698.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"1926_CR172","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/1096-911x(200008)35:2<91::aid-mpo1>3.0.co;2-g","volume":"35","author":"CA Sklar","year":"2000","unstructured":"Sklar CA, Mertens AC, Walter A, et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000;35(2):91\u20135. https:\/\/doi.org\/10.1002\/1096-911x(200008)35:2%3c91::aid-mpo1%3e3.0.co;2-g.","journal-title":"Med Pediatr Oncol"},{"issue":"4","key":"1926_CR173","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ctrv.2015.02.007","volume":"41","author":"G Ariaans","year":"2015","unstructured":"Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EG, Jalving M. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat Rev. 2015;41(4):376\u201384. https:\/\/doi.org\/10.1016\/j.ctrv.2015.02.007.","journal-title":"Cancer Treat Rev"},{"key":"1926_CR174","doi-asserted-by":"publisher","first-page":"eAO8031","DOI":"10.31744\/einstein_journal\/2022AO8031","volume":"20","author":"MTK Toyoshima","year":"2022","unstructured":"Toyoshima MTK, Cukier P, Souza ABC, Pereira J, Hoff AO, Nery M. Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study. Einstein (Sao Paulo). 2022;20:eAO8031. https:\/\/doi.org\/10.31744\/einstein_journal\/2022AO8031.","journal-title":"Einstein (Sao Paulo)"},{"issue":"11","key":"1926_CR175","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","volume":"21","author":"JW Goldman","year":"2016","unstructured":"Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia associated with targeted oncologic treatment: mechanisms and management. Oncologist. 2016;21(11):1326\u201336. https:\/\/doi.org\/10.1634\/theoncologist.2015-0519.","journal-title":"Oncologist"},{"issue":"57","key":"1926_CR176","first-page":"144","volume":"11","author":"M Scartozzi","year":"2011","unstructured":"Scartozzi M, Bianconi M, Maccaroni E, et al. State of the art and future perspectives for the use of insulin-like growth factor receptor\u00a01 (IGF-1R) targeted treatment strategies in solid tumors. Discov Med. 2011;11(57):144\u201353.","journal-title":"Discov Med"},{"issue":"11","key":"1926_CR177","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/sj.bmt.1703060","volume":"27","author":"N Sakata","year":"2001","unstructured":"Sakata N, Yasui M, Okamura T, Inoue M, Yumura-Yagi K, Kawa K. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10\/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant. 2001;27(11):1153\u201361. https:\/\/doi.org\/10.1038\/sj.bmt.1703060.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"1926_CR178","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/sj.leu.2402946","volume":"17","author":"R Schots","year":"2003","unstructured":"Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17(6):1150\u20136. https:\/\/doi.org\/10.1038\/sj.leu.2402946.","journal-title":"Leukemia"},{"issue":"2","key":"1926_CR179","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1055\/s-0029-1212086","volume":"107","author":"GS Hotamisligil","year":"1999","unstructured":"Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107(2):119\u201325. https:\/\/doi.org\/10.1055\/s-0029-1212086.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"1926_CR180","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1210\/jc.2004-2190","volume":"90","author":"N Pitteloud","year":"2005","unstructured":"Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636\u201341. https:\/\/doi.org\/10.1210\/jc.2004-2190.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1926_CR181","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2164\/jandrol.108.005454","volume":"29","author":"S Basaria","year":"2008","unstructured":"Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29(5):534\u20139. https:\/\/doi.org\/10.2164\/jandrol.108.005454.","journal-title":"J Androl"},{"issue":"1","key":"1926_CR182","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3803\/EnM.2017.32.1.23","volume":"32","author":"Y Hwangbo","year":"2017","unstructured":"Hwangbo Y, Lee EK. Acute hyperglycemia associated with anti-cancer medication. Endocrinol Metabol (Seoul). 2017;32(1):23\u20139. https:\/\/doi.org\/10.3803\/EnM.2017.32.1.23.","journal-title":"Endocrinol Metabol (Seoul)"},{"issue":"2","key":"1926_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020318","volume":"13","author":"MJ Abraham","year":"2023","unstructured":"Abraham MJ, El Sherbini A, El-Diasty M, Askari S, Szewczuk MR. Restoring epigenetic reprogramming with diet and exercise to improve health-related metabolic diseases. Biomolecules. 2023;13(2):318. https:\/\/doi.org\/10.3390\/biom13020318.","journal-title":"Biomolecules"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01926-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:33:52Z","timestamp":1791848032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01926-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":183,"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01926-9","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prahallad Mishra, Thyparambil Aravindakshan PramodKumar, Bhagyashree Pradhan, Utpal Ghosh, Pradyumna K. Mishra, Pujarini Dash, Ranjit Mohan Anjana, and Samir Kumar Patra declare that they have no conflict of interest. Viswanathan Mohan is an Editorial Board member of\n                      Diabetes Therapy\n                      . Viswanathan Mohan was not involved in the selection of peer reviewers for the manuscript nor any subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}